Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hemispherx unveils positive influenza data for Ampligen
In in vitro studies, Ampligen was combined with the neuraminidase inhibitors oseltamivir (brand name Tamiflu) and zanamivir (Relenza) and thereafter applied to cells in culture infected with an
In in vitro studies, Ampligen was combined with the neuraminidase inhibitors oseltamivir (brand name Tamiflu) and zanamivir (Relenza) and thereafter applied to cells in culture infected with an
The phase II, double blind, placebo-controlled study will evaluate the efficacy and safety of compound 751689 over a 12-month period. The study will enroll approximately 520 post-menopausal women
RPL554 is being developed for the treatment of hay fever and asthma, which are among the most prevalent respiratory diseases in the industrialised world. According to Verona Pharma,
The 24-week study investigated the efficacy and tolerability of Cipralex compared to duloxetine, which is marketed under the Cymbalta brand by US-based Eli Lilly. The research showed that
The placebo-controlled clinical study that showed Diachrome significantly improved glycemic control in patients with poorly controlled blood sugar levels who were being treated with oral anti-diabetic medication (OADs).
The so-called ACT 2 trial evaluated the efficacy and safety of the intravenous formulation of vernakalant hydrochloride (vernakalant (iv)) for the treatment of patients who developed atrial fibrillation
The five-year contract is valued at more than $500 million, with options that if exercised extend the value to $1.6 billion and the performance period of the contract.
The New Jersey-based biopharmaceutical company said that the drug had a favorable safety profile and promising anti-leukemic activity in patients with relapsed and refractory acute myelogenous leukemia and
The National Institute for Health and Clinical Excellence (NICE) published the proposal after the manufacturer, Janssen-Cilag, said it would refund the costs of treating patients if the therapy
The compound, tgAAC94, is an investigational therapeutic designed to inhibit the activity of tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation. The phase I/II study is designed